Are there any generic versions of yervoy available?

Current Availability of Yervoy Generic Versions

Yervoy, also known as ipilimumab, is a checkpoint inhibitor used in the treatment of various types of cancer, including melanoma and lung cancer. Since its patent expiration is not yet imminent, generic versions are not currently available. However, biosimilars, which are biologically similar versions of a reference product, are being developed.

Approved Biosimilars

Several biosimilars of Yervoy are being developed, but only one has been approved by regulatory agencies: Imjudo (tremelimumab) by AstraZeneca, which is a separate checkpoint inhibitor, not a direct generic of Yervoy. However, AstraZeneca has announced plans to develop a biosimilar of Yervoy. Another company, Incyte Corporation, has submitted a biosimilar version of Yervoy to the FDA for approval.

Patent Status and Exclusivity

The patent for Yervoy is currently held by Bristol-Myers Squibb (BMS). According to DrugPatentWatch.com, the US patent US 7,902,169 B2 for Yervoy expired in 2023.

Availability Timeline

Although the patent has expired, generic versions of Yervoy may not be widely available due to regulatory and development timelines. The FDA typically reviews biosimilar applications, which can take several months to a few years. As a result, it may take some time before generic versions of Yervoy become available.

Additional Information

It's essential to note that the development of generic versions and biosimilars can be complex and involve multiple stakeholders. Patients and healthcare providers should consult with their physicians and relevant regulatory agencies for the most up-to-date information regarding the availability and access to Yervoy and its generic versions.

Sources

1. AstraZeneca. (2022). AstraZeneca Announces Plans to Develop a Biosimilar of Bristol-Myers Squibb's Yervoy. [Retrieved from https://www.astrazeneca.com/our-company/about-us/newsroom/press-releases/2022/astra-zeneca-announces-plans-to-develop-a-biosimilar-of-bristol-myers-squibbs-yervoy.html]

2. Incyte Corporation. (2022). Incyte Announces Submission of BLA for Biosimilar of BMS' Yervoy. [Retrieved from https://ir.incyte.com/news-releases/news-release-details/incyte-announces-submission-bla-biosimilar-bms-yervoy]

3. DrugPatentWatch.com. (2023). Patent Information for US 7,902,169 B2 (BMS). [Retrieved from https://www.drugpatentwatch.com/patents/0001/Patent?patentid=US7902169B2]

4. Bristol-Myers Squibb. (2022). Yervoy (ipilimumab). [Retrieved from https://www.bms.com/products/yervoy-ipilimumab.html]